|本期目录/Table of Contents|

[1]余春辉 胡雁南 邵鑫 郎希龙 徐志云.感染性心内膜炎术后院内死亡危险因素分析[J].国际心血管病杂志,2018,05:296-300.
　YU Chunhui,HU Yannan,SHAO Xin,et al.In-hospital mortality risk factors analysis of postoperative infective endocarditis[J].International Journal of Cardiovascular Disease,2018,05:296-300.
点击复制

感染性心内膜炎术后院内死亡危险因素分析(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年05期
页码:
296-300
栏目:
临床研究
出版日期:
2019-02-01

文章信息/Info

Title:
In-hospital mortality risk factors analysis of postoperative infective endocarditis
作者:
余春辉 胡雁南 邵鑫 郎希龙 徐志云
Author(s):
YU Chunhui;  HU Yannan;  SHAO Xin;  LANG Xilong;  XU Zhiyun
Department of Cardiovascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
关键词:
感染性心内膜炎;  外科治疗;  危险因素
Keywords:
Infective endocarditis;  Surgical treatment;  Risk factors
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.05.011
文献标识码:
-
摘要:
目的:探讨感染性心内膜炎患者术后院内死亡的危险因素,优化围术期管理。方法:连续纳入307例接受手术治疗的成人感染性心内膜炎患者,其中术后院内死亡19例。Logistic回归分析感染性心内膜炎患者术后院内死亡的危险因素,受试者工作特征曲线检验危险因素的预测能力,约登指数计算危险因素的临界值。结果:心功能Ⅳ级、白细胞计数、体外循环时间、术后气管插管时间是感染性心内膜炎患者术后院内死亡的独立危险因素。心功能Ⅳ级的预测准确率为75.2%。白细胞计数的预测准确率为75.4%,临界值为9.5×10
Abstract:
Objective:This study aims to investigate the risk factors of in-hospital postoperative death in patients with infective endocarditis and to optimize perioperative management.Methods:A total of 307 adult patients with infective endocarditis who underwent s

参考文献/References


[1] Gatti G, Benussi B, Gripshi F, et al. A risk factor analysis for in-hospital mortality after surgery for infective endocarditis and a proposal of a new predictive scoring system[J]. Infection, 2017, 45(4):413-423.
[2] David TE, Gavra G, Feindel CM, et al. Surgical treatment of active infective endocarditis: a continued challenge[J]. J Thorac Cardiovasc Surg, 2007, 133(1):144-149.
[3] De Feo M, Cotrufo M, Carozza A, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery[J]. Scientific World Journal, 2012, 2012:307571.
[4] Gaca JG, Sheng S, Daneshmand MA, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system[J]. J Thorac Cardiovasc Surg, 2011, 141(1):98-106.
[5] Olmos C, Vilacosta I, Habib G, et al. Risk score for cardiac surgery in active left-sided infective endocarditis[J]. Heart, 2017, 103(18):1435-1442.
[6] Machado MN, Nakazone MA, Murad-Júnior JA, et al. Surgical treatment for infective endocarditis and hospital mortality in a Brazilian single-center[J]. Rev Bras Cir Cardiovasc, 2013, 28(1):29-35.
[7] AATS Surgical Treatment of Infective Endocarditis Consensus Guidelines Writing Committee Chairs, Pettersson GB, Coselli JS, et al. 2016 the American association for thoracic surgery(AATS)consensus guidelines: surgical treatment of infective endocarditis: executive summary[J]. J Thorac Cardiovasc Surg, 2017, 153(6):1241-1258..
[8] Fayad G, Vincentelli A, Leroy G, et al. Impact of antimicrobial therapy on prognosis of patients requiring valve surgery during active infective endocarditis[J]. J Thorac Cardiovasc Surg, 2014, 147(1):254-258.
[9] Ostrowski S, Kasielski M, Kordiak J, et al. Myocardial oxidative stress in patients with active infective endocarditis[J]. Int J Cardiol, 2013, 167(1):270-276.
[10] Oliver L, Lepeule R, Moussafeur A, et al. Early surgery in infective endocarditis: why should we wait?[J]. Arch Cardiovasc Dis, 2016, 109(12):651-654.
[11] Dunne B, Marr T, Kim D, et al. Infective endocarditis[J]. Lancet, 2014, 23(7):628-635.
[12] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology(ESC). Endorsed by: European Association for Cardio-Thoracic Surgery(EACTS), the European Association of Nuclear(EANM)[J]. Eur Heart J, 2015, 36(44):3075-3128.
[13] Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update[J]. Eur J Cardiothorac Surg, 2002, 21(2):232-244.
[14] Wan S, Leclerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies[J]. Chest, 1997, 112(3):676-692.
[15] Di Tomasso N, Monaco F, Landoni G. Hepatic and renal effects of cardiopulmonary bypass[J]. Best Pract Res Clin Anaesthesiol, 2015, 29(2):151-161.
[16] Yamauchi T, Miyagawa S, Yoshikawa Y, et al. Risk index for postoperative acute kidney injury after valvular surgery using cardiopulmonary bypass[J]. Ann Thorac Surg, 2017, 104(3):868-875.
[17] Augoustides JG. The inflammatory response to cardiac surgery with cardiopulmonary bypass: should steroid prophylaxis be routine?[J]. J Cardiothorac Vasc Anesth, 2012, 26(5):952-958.
[18] Salis S, Mazzanti VV, Salvi L, et al. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery [J]. J Cardiothorac Vasc Anesth, 2008, 22(6):814-822.
[19] Salsano A, Giacobbe DR, Sportelli E, et al. Aortic cross-clamp time and cardiopulmonary bypass time: prognostic implications in patients operated on for infective endocarditis[J]. Interact Cardiovasc Thorac Surg, 2018, 27(3):328-335.
[20] Reddy SL, Grayson AD, Griffiths EM, et al. Logistic risk model for prolonged ventilation after adult cardiac surgery[J]. Ann Thorac Surg, 2007, 84(2):528-536.
[21] Sharma V, Rao V, Manlhiot C, et al. A derived and validated score to predict prolonged mechanical ventilation in patients undergoing cardiac surgery[J]. J Thorac Cardiovasc Surg, 2017, 153(1):108-115.
[22] Devarajan J, Vydyanathan A, Xu M, et al. Early tracheostomy is associated with improved outcomes in patients who require prolonged mechanical ventilation after cardiac surgery[J]. J Am Coll Surg, 2012, 214(6):1008-1016.e4.
[23] Grubitzsch H, Schaefer A, Melzer C, et al. Outcome after surgery for prosthetic valve endocarditis and the impact of preoperative treatment[J]. J Thorac Cardiovasc Surg, 2014, 148(5):2052-2059.
[24] Tugtekin S, Matschke K, Daubner D, et al. Prosthetic valve endocarditis: importance of surgical treatment[J]. Thorac Cardiovasc Surg, 2007, 55(2):94-98.
[25] Grubitzsch H, Tarar W, Claus B, et al. Risks and challenges of surgery for aortic prosthetic valve endocarditis[J]. Heart Lung Circ, 2018, 27(3):333-343.
[26] Perrotta S, Jeppsson A, Fröjd V, et al. Surgical treatment of aortic prosthetic valve endocarditis: a 20-year single-center experience[J]. Ann Thorac Surg, 2016, 101(4):1426-1432.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81570351)
作者单位:200082 上海,海军军医大学附属长海医院心血管外科
通信作者:郎希龙,Email:langxl666@sohu.com
更新日期/Last Update: 2018-09-30